TY - JOUR
T1 - Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction
AU - Goldenberg, Ido
AU - Mor, Tal
AU - Nof, Eyal
AU - Younis, Arwa
AU - Berkovitch, Anat
AU - Rosso, Raphael
AU - Barsheshet, Alon
AU - Suleiman, Mahmoud
AU - Beinart, Roy
N1 - Publisher Copyright:
© Published on behalf of the European Society of Cardiology. All rights reserved.The Author(s) 2019.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Aims Heart failure patients with advanced chronic kidney disease (CKD) may experience an increased rate of non-arrhythmic mortality due to associated comorbidities. We aimed to evaluate the risk of mortality without appropriate implantable cardioverter-defibrillator (ICD) shocks in this high-risk population. Methods and results The study population comprised 3542 patients who received an ICD, were enrolled, and prospectively followed-up in the Israeli ICD registry. Study patients were categorized into two groups: those with advanced CKD [defined by a glomerular filtration rate of <30 mL/min/1.73 m 2 or being on dialysis at time of implantation (n = 197)], and those without advanced CKD (n = 3344). The primary endpoint was the risk of death without receiving appropriate ICD shock. Kaplan-Meier survival analysis showed that at 5 years of follow-up the rates of death without prior ICD shock were significantly higher in the advanced kidney disease group (46%) compared with the non-advanced CKD group (19%; log-rank P-value <0.001). Consistently, multivariate analysis showed that the risk of death without receiving appropriate ICD shock therapy at 5 years was 2.5-fold (P < 0.001) higher among advanced CKD patients. In contrast, the rate of appropriate ICD shock therapy at 5 years among advanced CKD patients was only 9%, with a very high mortality rate (63%) within 3.5 years subsequent to shock therapy. Conclusion Nearly one-half of ICD with advanced CKD die within 5 years without receiving an appropriate ICD shock. These findings stress the importance of appropriate patient selection for primary ICD implantation in this high-risk population.
AB - Aims Heart failure patients with advanced chronic kidney disease (CKD) may experience an increased rate of non-arrhythmic mortality due to associated comorbidities. We aimed to evaluate the risk of mortality without appropriate implantable cardioverter-defibrillator (ICD) shocks in this high-risk population. Methods and results The study population comprised 3542 patients who received an ICD, were enrolled, and prospectively followed-up in the Israeli ICD registry. Study patients were categorized into two groups: those with advanced CKD [defined by a glomerular filtration rate of <30 mL/min/1.73 m 2 or being on dialysis at time of implantation (n = 197)], and those without advanced CKD (n = 3344). The primary endpoint was the risk of death without receiving appropriate ICD shock. Kaplan-Meier survival analysis showed that at 5 years of follow-up the rates of death without prior ICD shock were significantly higher in the advanced kidney disease group (46%) compared with the non-advanced CKD group (19%; log-rank P-value <0.001). Consistently, multivariate analysis showed that the risk of death without receiving appropriate ICD shock therapy at 5 years was 2.5-fold (P < 0.001) higher among advanced CKD patients. In contrast, the rate of appropriate ICD shock therapy at 5 years among advanced CKD patients was only 9%, with a very high mortality rate (63%) within 3.5 years subsequent to shock therapy. Conclusion Nearly one-half of ICD with advanced CKD die within 5 years without receiving an appropriate ICD shock. These findings stress the importance of appropriate patient selection for primary ICD implantation in this high-risk population.
KW - Appropriate shock
KW - Chronic kidney disease
KW - Implantable cardioverter-defibrillator
UR - http://www.scopus.com/inward/record.url?scp=85062397909&partnerID=8YFLogxK
U2 - 10.1093/europace/euy305
DO - 10.1093/europace/euy305
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30689821
AN - SCOPUS:85062397909
SN - 1099-5129
VL - 21
SP - 459
EP - 464
JO - Europace
JF - Europace
IS - 3
ER -